Reneo Pharmaceuticals: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Reneo Pharmaceuticals (NASDAQ:RPHM) reported Q4 earnings with an EPS of $-0.7, missing estimates by -13.0% and showing no revenue change from the previous year. Despite missing EPS estimates last quarter, the share price increased by 1.0% the following day.
March 28, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Reneo Pharmaceuticals reported a Q4 EPS of $-0.7, missing estimates by -13.0%, with no change in revenue from the previous year.
Missing earnings estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the previous quarter's miss was followed by a slight increase in share price, indicating that market reactions can be unpredictable.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100